November is IBD Awareness Month. Inflammatory bowel disease includes Crohn’s disease, ulcerative colitis, and many other disorders. Evidence is accruing that medical cannabis has the potential to positively impact the symptoms of those suffering from IBD and, according to the Canadian Digestive Health Foundation (CDHF), 15-20% of patients in Canada and the US already use medical cannabis to relieve their IBD symptoms.
As part of our commitment to medical cannabis education, Spectrum Therapeutics has partnered with the CDHF to develop educational content on their website and a comprehensive guide for you to download. Medical Cannabis and Gastrointestinal Disorders: An Overview for Healthcare Professionals contains information about cannabinoid medicine, dosing, clinical evidence, and safety considerations for healthcare professionals who are using, or want to use, medical cannabis for their patients with gastrointestinal disorders.
The CDHF has also launched a social media campaign to raise awareness during the months of November and December. Follow this campaign on Facebook for more current info on medical cannabis and IBD https://www.facebook.com/CDHFdn/.
This educational material was made possible by an unrestricted educational grant to the CDHF from Spectrum Therapeutics/Canopy Growth Corporation.